Psychosocial Outcomes and Drug Attributes Affecting Treatment Choice in Men Receiving Sildenafil Citrate and Tadalafil for the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Open-Label, Crossover Study
- 1 July 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 3 (4), 650-661
- https://doi.org/10.1111/j.1743-6109.2006.00261.x
Abstract
Introduction. Although sildenafil citrate (sildenafil) and tadalafil are efficacious and well-tolerated treatments for erectile dysfunction (ED), preference studies have shown that patients may favor one medication over the other. Aim. To determine whether psychosocial outcomes differed when men with ED received tadalafil compared with sildenafil. Main Outcome Measures. Measures included a treatment preference question, Psychological and Interpersonal Relationship Scales (PAIRS), and Drug Attribute Questionnaire. Methods. Randomized, open-label, crossover study. After a 4-week baseline, men with ED (N = 367; mean age = 54 years; naive to type 5 phosphodiesterase inhibitor therapy) were randomized: tadalafil for 12 weeks then sildenafil for 12 weeks or vice versa (8-week dose optimization/4-week assessment phases). During dose optimization, patients started with 10 mg tadalafil, or 25 or 50 mg sildenafil and could titrate to their optimal dose (10 or 20 mg tadalafil; 25, 50, or 100 mg sildenafil). Medications were taken as needed. Patients completing both 12-week periods chose which medication to continue during an 8-week extension. Results. Of 291 men completing both treatment periods, 71% (N = 206) chose tadalafil and 29% (N = 85) chose sildenafil (P < 0.001) for the 8-week extension. When taking tadalafil compared with sildenafil men had higher mean endpoint scores on PAIRS Sexual Self-Confidence (tadalafil = 2.91 vs. sildenafil = 2.75; P < 0.001) and Spontaneity (tadalafil = 3.32 vs. sildenafil = 3.17; P < 0.001) Domains and a lower mean endpoint score on Time Concerns Domain (tadalafil = 2.2 vs. sildenafil = 2.59; P < 0.001). The two most frequently chosen drug attributes to explain treatment preference were ability to get an erection long after taking the medication and firmness of erections. Tadalafil and sildenafil were well tolerated with 12 (3.3%) patients discontinuing for an adverse event. Conclusions. As measured with PAIRS, men with ED had higher sexual self-confidence and spontaneity and less time concerns related to sexual encounters when treated with tadalafil compared with sildenafil. These psychosocial outcomes may help explain why more men (71%) preferred tadalafil for the treatment of ED in this clinical trialKeywords
Funding Information
- Lilly ICOS LLC. (H6D-MC-LVFL)
This publication has 24 references indexed in Scilit:
- The Efficacy of Tadalafil in Clinical PopulationsThe Journal of Sexual Medicine, 2005
- Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference)The American Journal of Cardiology, 2005
- Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trialsDiabetologia, 2004
- Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levelsClinical Endocrinology, 2004
- TADALAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING BILATERAL NERVE SPARING RADICAL RETROPUBIC PROSTATECTOMY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIALJournal of Urology, 2004
- Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patientsSpinal Cord, 2004
- Quality of life and erectile dysfunctionUrology, 2002
- Patient Choice is Critical in Managing Erectile DysfunctionEuropean Urology Supplements, 2002
- When an erection alone is not enough: biopsychosocial obstacles to lovemakingInternational Journal Of Impotence Research, 2002
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998